EDITGENE

Background Established in August 2017, EDITGENE is a leading genomic technology company based in Guangzhou, China. Founded and guided by a team of distinguished professors, EDITGENE integrates diverse expertise and advanced scientific methodologies gained through global research experiences. The company is at the forefront of developing CRISPR/Cas-based genomic editing technologies, with a commitment to delivering innovative solutions that advance human health and improve lives. EDITGENE's capabilities span research, development, production, and services, enabling impactful contributions to the scientific and healthcare communities. Vision Driven by its core philosophy of "innovation and sharing of scientific knowledge," EDITGENE focuses on advancing science in the domains of life, health, sustainability, and development. Building on CRISPR/Cas technologies, the company has pioneered platforms such as CRISPR-EDITx™, Bingo™, FASST, and LION™ setting new benchmarks in prime editing. EDITGENE is dedicated to expanding the accessibility and applicability of CRISPR/Cas technologies to promote breakthroughs in human health and genomic research. By providing comprehensive CRO services to global research laboratories and pharmaceutical companies, EDITGENE contributes to accelerating genomic advancements worldwide. From Research to Practice EDITGENE bridges the gap between research and practical applications by refining CRISPR technologies for real-world use. The company contributes to disease prevention, diagnosis, and treatment by collaborating with pharmaceutical companies to develop effective therapeutic solutions. With a commitment to excellence in scientific innovation, production, and service delivery, EDITGENE aims to lead the biotechnology industry. Its mission is to advance human health through transformative science, creating a continuous cycle of development that meets the highest standards of quality and impact for the scientific community and society.